Ananda Pharma CEO says name change reflects focus on drug development; patient dosing expected in 2025 [Video]

Ananda Pharma Plc (AQSE:ANA) co-founder and CEO Melissa Sturgess talked with Proactive’s Stephen Gunnion about the company’s evolution and progress in cannabinoid-based drug development. Sturgess shared the significance of the recent name change from Ananda Developments to Ananda Pharma, reflecting the company’s focus on developing pharmaceutical-grade cannabinoid medicines.

She highlighted collaborations with key opinion leaders in areas like chemotherapy-induced pain, endometriosis, and refractory epilepsy. These partnerships have enabled the company to secure non-dilutive government funding for its two Phase 2 and two Phase 3 clinical trials, with patient dosing expected in 2025.

Additionally, Sturgess discussed the company’s recent £150,000 investment from new investors and a successful £2 million fundraising in September, backed by its chairman and largest shareholder. This financial support positions Ananda Pharma to advance its clinical trials and regulatory preparations for global markets.

Looking ahead to 2025, Sturgess emphasised the importance of licensed cannabinoid medicines, predicting significant market growth and regulatory progress …